** Shares of drug developer Tevogen Bio TVGN.O rise ~48% to $2 premarket
** On Friday, TVGN said it is expanding its partnership with Microsoft MSFT.O to use AI to improve its immunotherapy treatments
** Co's proprietary tech, PredicTcell, will be developed on Microsoft's Azure cloud platform to identify precise T-cell targets - TVGN
** TVGN said it is also using MSFT's AI tools and Azure cloud platform to proactively investigate potential treatments for human papillomavirus - viral infection that can cause genital warts and certain types of cancer
** Last year, TVGN announced its partnership with Microsoft, and its shares surged to ~54%
** TVGN fell 90.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.